Source: Reuters Health News
According to a report by Reuters Health News, the US Food and Drug Administration (FDA) has approved aflibercept injection (Eylea) for macular oedema following central retinal vein occlusion (CRVO). The recommended dose is 2 mg every 4 weeks. The approval is based on the outcomes of two phase III studies: COPERNICUS and GALILEO.
[Editor's note: The US FDA has already approved aflibercept injection for neovascular (wet) age-related macular degeneration, whilst the EMA has issued a positive opinion recommending the approval of a marketing authorisation for this indication. Please see NeLM link below.]